Table 2.
Main demographic and clinical characteristics of patients in included studies
| Study | Sample size | PPA variant | Age (M ± SD) | Sex ratio (M/F) | Education years (M ± SD) | Years post-onset (M ± SD) | MMSE (M ± SD) |
|---|---|---|---|---|---|---|---|
| Cotelli et al. (2014) | 16 (8 active, 8 sham) | 16 nfvPPA | 66.9 ± 8.2 (active: 63.4 ± 6.8, sham: 70.4 ± 6.8) | 6/10 (active: 3/5, sham: 3/5) | 8.2 ± 3.1 (active: 9.3 ± 3.2, sham: 7.1 ± 3.2) | Not specified | 18.3 ± 4.5 (active: 18.0 ± 2.9, sham: 18.6 ± 2.9) |
| McConathey et al. (2017) | 7 | 6 nfvPPA, 1 lvPPA | 68.71 ± 6.97 | 2/5 | 13.86 ± 2.73 | 4.29 ± 1.89 | 24.40 ± 4.77 |
| Roncero et al. (2017) | 10 | 6 nfvPPA, 2 lvPPA, 2 svPPA | 67.4 ± 6.26 | 7/3 | 14.9 ± 3.48 | Not specified | 18.2 ± 7.97 |
| Ferrucci et al. (2018) | 5 | Not specified | 68.8 ± 4.66 | 3/2 | 14 ± 4.18 | Not specified | 24.6 ± 3.05 |
| Hosseini et al. (2019) | 6 | 3 nfvPPA, 3 lvPPA | 67 ± 10.6 | 2/4 | 14.3 ± 3.2 | 4.8 ± 1.6 | 26.8 ± 2.3 |
| Benussi et al. (2020) | 30 (19 active, 11 sham) | 18 nfvPPA, 12 svPPA | Active: 62.72 ± 7.02, sham: 64.05 ± 8 | Active: 62.72 ± 7.02, sham: 64.05 ± 8 | Active: 12.11 ± 4.45, sham: 12.1 ± 3.02 | Active: 2.97 ± 1.86, sham: 2.80 ± 1.98 | Active: 18.63 ± 10.93, sham: 20.1 ± 8.48 |
| de Aguiar et al., (2020a, 2020b) | 40 (21 active, 19 sham) at pre- and post, 37 (19 active, 18 sham) at fu1, 36 (17 active, 19 sham) at fu2 | 15 nfvPPA, 8 svPPA, 17 lvPPA | 67.68 ± 6.76 (active: 66.1 ± 7.7, sham: 69.4 ± 5.1) | 22/18 (active: 12/9, sham: 10/9) | Not specified | 4.75 ± 2.87 | Not specified |
| Pytel et al. (2021) | 20 (20 active, 7 sham) | 14 nfvPPA, 6 svPPA | Active: 66.95 ± 7.24, sham: 66.14 ± 7.31 | Active: 8/12, sham: 3/4 | Active: 13.40 ± 4.38, sham: 13.86 ± 3.18 | Active: 3.80 ± 3.90, sham: 3.71 ± 1.79 | Not specified |
| Nissim et al. (2022) | 11 | 2 nfvPPA, 2 svPPA, 7 lvPPA | 66.55 ± 6.85 (tDCS: 66.29 ± 7.67, sham: 67 ± 6.16) | 7/4 (tDCS: 4/3, sham: 3/1) | Not specified | 3.64 ± 1.69 (tDCS: 4.14 ± 1.86, sham: 2.75 ± 0.96) | 24.09 ± 2 0.63 (active: 23.14 ± 2.34, sham: 25.75 ± 2.5) |
| Wang et al. (2022) | 36 (18 active, 18 sham) | 13 nfvPPA, 9 svPPA, 14 lvPPA | Active: 66.17 ± 7.49, sham: 69.72 ± 5.42 | 19/17 (active: 9/9, sham: 10/8) | Not specified | Active: 5.17 ± 3.40, sham: 4.72 ± 2.55 | Not specified |
| Borrego-Ecijia et al. (2023) | 13 | 5 nfvPPA, 4 svPPA, 4 lvppa | 64 ± 8.56 | 4/9 | Not specified | 4.1 ± 1.8 | 24.62 ± 3.1 |
| Huang et al. (2023) | 35 (18 active, 17 sham) | 14 nfvPPA, 10 svPPA, 11 lvPPA | Not specified | 16/19 (active: 8/10, sham: 8/9) | Not specified | Median () in months: 24.0 (9.0–36.0); active: 24.0 (6 – 24.0), sham (M ± SD): 38.9 ± 28.9 | Median (IQR): 22.0 (21.0–24.0); active (M ± SD): 22.0 ± 2.0, sham (M ± SD) 23.1 ± 2.0 |
aIQR inter-quartile range